JP2018533622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533622A5 JP2018533622A5 JP2018535266A JP2018535266A JP2018533622A5 JP 2018533622 A5 JP2018533622 A5 JP 2018533622A5 JP 2018535266 A JP2018535266 A JP 2018535266A JP 2018535266 A JP2018535266 A JP 2018535266A JP 2018533622 A5 JP2018533622 A5 JP 2018533622A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- group
- agent
- meibomian gland
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 21
- 229940079593 drugs Drugs 0.000 claims 13
- -1 thixocortol Chemical compound 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 5
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims 4
- 210000000744 Eyelids Anatomy 0.000 claims 4
- 210000004175 Meibomian Glands Anatomy 0.000 claims 4
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims 4
- 229960000830 captopril Drugs 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 3
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2S)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 claims 2
- IXELFRRANAOWSF-ALCCZGGFSA-N (Z)-Ajoene Chemical compound C=CCSS\C=C/CS(=O)CC=C IXELFRRANAOWSF-ALCCZGGFSA-N 0.000 claims 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-Ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 claims 2
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 claims 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 2
- 229940093530 Coenzyme A Drugs 0.000 claims 2
- JBJSVEVEEGOEBZ-PSASIEDQSA-N Coenzyme B Chemical compound OP(=O)(O)O[C@H](C)[C@H](C(O)=O)NC(=O)CCCCCCS JBJSVEVEEGOEBZ-PSASIEDQSA-N 0.000 claims 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N Cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 2
- 229940119025 Cysteamine Drugs 0.000 claims 2
- WQABCVAJNWAXTE-UHFFFAOYSA-N Dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 claims 2
- 229960001051 Dimercaprol Drugs 0.000 claims 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N Disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 2
- 229960002563 Disulfiram Drugs 0.000 claims 2
- JTLXCMOFVBXEKD-FOWTUZBSSA-N Fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 229960003180 Glutathione Drugs 0.000 claims 2
- 108010024636 Glutathione Proteins 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- 229960003151 Mercaptamine Drugs 0.000 claims 2
- MQBCDKMPXVYCGO-FQBKTPCVSA-N Mycothiol Chemical compound CC(=O)N[C@@H](CS)C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O MQBCDKMPXVYCGO-FQBKTPCVSA-N 0.000 claims 2
- XWKKYVJREGXHFO-BYPYZUCNSA-N Ovothiol A Chemical compound CN1C=NC(S)=C1C[C@H](N)C(O)=O XWKKYVJREGXHFO-BYPYZUCNSA-N 0.000 claims 2
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims 2
- 229950007142 Prosultiamine Drugs 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 229960003703 Sodium thiosalicylate Drugs 0.000 claims 2
- ACTRVOBWPAIOHC-UHFFFAOYSA-N Succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 claims 2
- CKHJPWQVLKHBIH-ZDSKVHJSSA-N Sulbutiamine Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SS\C(CCOC(=O)C(C)C)=C(\C)N(C=O)CC1=CN=C(C)N=C1N CKHJPWQVLKHBIH-ZDSKVHJSSA-N 0.000 claims 2
- LJJKNPQAGWVLDQ-SNVBAGLBSA-N Thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 claims 2
- 108010036928 Thiorphan Proteins 0.000 claims 2
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N Thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 claims 2
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims 2
- IAIDUHCBNLFXEF-MNEFBYGVSA-N Zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims 2
- 235000010081 allicin Nutrition 0.000 claims 2
- 229960004272 bucillamine Drugs 0.000 claims 2
- 239000005516 coenzyme A Substances 0.000 claims 2
- 150000002019 disulfides Chemical class 0.000 claims 2
- 229950006836 fursultiamine Drugs 0.000 claims 2
- 239000003410 keratolytic agent Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 2
- 235000019136 lipoic acid Nutrition 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108010074581 mycothiol Proteins 0.000 claims 2
- 229960001639 penicillamine Drugs 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 229960003211 sulbutiamine Drugs 0.000 claims 2
- 229960002663 thioctic acid Drugs 0.000 claims 2
- 229940103494 thiosalicylic acid Drugs 0.000 claims 2
- 229960004402 tiopronin Drugs 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 229960002769 zofenopril Drugs 0.000 claims 2
- 229960000458 Allantoin Drugs 0.000 claims 1
- 239000004342 Benzoyl peroxide Substances 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 229940108066 Coal Tar Drugs 0.000 claims 1
- 229960002433 Cysteine Drugs 0.000 claims 1
- FVIGODVHAVLZOO-UHFFFAOYSA-N Dixanthogen Chemical compound CCOC(=S)SSC(=S)OCC FVIGODVHAVLZOO-UHFFFAOYSA-N 0.000 claims 1
- ZFFTZDQKIXPDAF-UHFFFAOYSA-N Furan-2-ylmethanethiol Chemical compound SCC1=CC=CO1 ZFFTZDQKIXPDAF-UHFFFAOYSA-N 0.000 claims 1
- YRSVDSQRGBYVIY-GJZGRUSLSA-N Gemopatrilat Chemical compound O=C1N(CC(O)=O)C(C)(C)CCC[C@@H]1NC(=O)[C@@H](S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-GJZGRUSLSA-N 0.000 claims 1
- 229950006480 Gemopatrilat Drugs 0.000 claims 1
- 210000004907 Glands Anatomy 0.000 claims 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims 1
- 239000004201 L-cysteine Substances 0.000 claims 1
- 235000013878 L-cysteine Nutrition 0.000 claims 1
- 229960000448 Lactic acid Drugs 0.000 claims 1
- DZKOKXZNCDGVRY-UHFFFAOYSA-N Lenthionine Chemical compound C1SSCSSS1 DZKOKXZNCDGVRY-UHFFFAOYSA-N 0.000 claims 1
- 229940046307 SODIUM THIOGLYCOLATE Drugs 0.000 claims 1
- 229910018165 SeH Inorganic materials 0.000 claims 1
- 229940055619 Selenocysteine Drugs 0.000 claims 1
- ZKZBPNGNEQAJSX-REOHCLBHSA-N Selenocysteine Chemical compound [SeH]C[C@H](N)C(O)=O ZKZBPNGNEQAJSX-REOHCLBHSA-N 0.000 claims 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims 1
- JNMWHTHYDQTDQZ-UHFFFAOYSA-N Selsun Blue Chemical compound S=[Se]=S JNMWHTHYDQTDQZ-UHFFFAOYSA-N 0.000 claims 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims 1
- 229960001727 Tretinoin Drugs 0.000 claims 1
- 229940045136 Urea Drugs 0.000 claims 1
- 230000011759 adipose tissue development Effects 0.000 claims 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims 1
- 235000019400 benzoyl peroxide Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000004327 boric acid Substances 0.000 claims 1
- 229960002645 boric acid Drugs 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 229960000539 carbamide Drugs 0.000 claims 1
- 239000011280 coal tar Substances 0.000 claims 1
- 229960002377 dixanthogen Drugs 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 235000003969 glutathione Nutrition 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 230000000414 obstructive Effects 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229910000338 selenium disulfide Inorganic materials 0.000 claims 1
- 229960005265 selenium sulfide Drugs 0.000 claims 1
- 235000016491 selenocysteine Nutrition 0.000 claims 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562233906P | 2015-09-28 | 2015-09-28 | |
| US201562233941P | 2015-09-28 | 2015-09-28 | |
| US62/233,906 | 2015-09-28 | ||
| US62/233,941 | 2015-09-28 | ||
| PCT/IB2016/001510 WO2017055924A2 (fr) | 2015-09-28 | 2016-09-28 | Agents contenant un thiol et un disulfure permettant d'augmenter la sécrétion lipidique des glandes de meibomius |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020206141A Division JP7138694B2 (ja) | 2015-09-28 | 2020-12-11 | マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018533622A JP2018533622A (ja) | 2018-11-15 |
| JP2018533622A5 true JP2018533622A5 (fr) | 2019-09-05 |
Family
ID=58408743
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535266A Pending JP2018533622A (ja) | 2015-09-28 | 2016-09-28 | マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤 |
| JP2020206141A Active JP7138694B2 (ja) | 2015-09-28 | 2020-12-11 | マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020206141A Active JP7138694B2 (ja) | 2015-09-28 | 2020-12-11 | マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10688122B2 (fr) |
| EP (1) | EP3313413A4 (fr) |
| JP (2) | JP2018533622A (fr) |
| KR (1) | KR20180090251A (fr) |
| CN (2) | CN113144203A (fr) |
| AU (1) | AU2016332966A1 (fr) |
| CA (1) | CA3000088A1 (fr) |
| WO (1) | WO2017055924A2 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| EP3313413A4 (fr) * | 2015-09-28 | 2018-07-11 | Azura Opthalmics Ltd. | Agents contenant un thiol et un disulfure permettant d'augmenter la sécrétion lipidique des glandes de meibomius |
| KR102541236B1 (ko) * | 2017-03-29 | 2023-06-08 | 아주라 오프탈믹스 엘티디 | 마이봄샘 지질 분비 증가를 위한 작용제 |
| BR112020012018A2 (pt) | 2017-12-15 | 2020-11-24 | Tarsus Pharmaceuticals, Inc. | formulações de parasiticida de isoxazolina e métodos para tratar blefarite |
| WO2019175290A1 (fr) | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis ou compositions dérivées du cannabis pour favoriser l'arrêt de la dépendance chimique |
| WO2020092402A1 (fr) * | 2018-10-30 | 2020-05-07 | Harrow Health, Inc. | Compositions pharmaceutiques de tiopronine et leurs procédés de préparation |
| WO2020208418A1 (fr) * | 2019-04-12 | 2020-10-15 | Azura Ophthalmics Ltd. | Compositions et procédés pour le traitement d'inconfort des lentilles de contact |
| JP2023513654A (ja) * | 2019-11-04 | 2023-04-03 | アズーラ オフサルミックス エルティーディー． | 眼または眼の周囲における障害のための計量投与量 |
| CA3166057A1 (fr) * | 2020-01-02 | 2021-07-08 | Azura Ophthalmics Ltd. | Fabrication de compositions de disulfure de selenium |
| CA3166357A1 (fr) | 2020-01-10 | 2021-07-15 | Azura Ophthalmics Ltd. | Instructions pour composition et sensibilite |
| CA3199736A1 (fr) | 2020-11-23 | 2022-05-27 | Sight Sciences, Inc. | Formulations et procedes de traitement d'affections de l'?il |
| CN112569179B (zh) * | 2020-12-25 | 2022-12-27 | 上海交通大学医学院附属第九人民医院 | 一种可注射水凝胶体系及其制备方法 |
| WO2023215244A1 (fr) * | 2022-05-02 | 2023-11-09 | Georgetown University | Utilisation de n-acétylcystéine pour traiter des troubles lipidiques et des dysfonctionnements d'organes associés |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3236730A (en) | 1962-01-04 | 1966-02-22 | Miles Lab | Blepharitis composition comprising antiseptic, quaternary ammonium compound, keratolytic agent and a chelating compound |
| US5602130A (en) | 1987-03-20 | 1997-02-11 | Allergan | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| JP2891883B2 (ja) * | 1993-11-05 | 1999-05-17 | 学校法人近畿大学 | 抗白内障医薬組成物 |
| WO1997020578A1 (fr) * | 1995-12-04 | 1997-06-12 | University Of Miami | Corticosteroide sans conservateur pour application locale, destine au traitement du syndrome de l'oeil sec, de la keratite filamenteuse, et du retard de clairance lacrymale |
| US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| EP0930072A1 (fr) | 1998-01-13 | 1999-07-21 | Kartar Dr. Lalvani | Composition à base de minéraux et de vitamines, pour le traitement de l'oeil sec |
| US6348508B1 (en) | 2000-04-04 | 2002-02-19 | Bausch & Lomb Incorporated | Method for treating dry eye |
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| DE60218511T2 (de) | 2001-10-26 | 2007-10-25 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| FR2833268B1 (fr) | 2001-12-12 | 2005-07-08 | Fabre Pierre Dermo Cosmetique | Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation |
| KR100564386B1 (ko) | 2002-05-13 | 2006-03-27 | 주식회사 마이코플러스 | 4-하이드록시-5-메톡시-4-[2-메틸-3-(3-메틸-2-부테닐)-2-옥시란닐]-1-옥사스피로[2,5]옥탄-6-온을 함유한 지루치료용 약제학적 조성물 |
| US8420699B1 (en) * | 2002-06-19 | 2013-04-16 | Irvine L. Dubow | Composition and methods of treatment using deionized and ozonated solution |
| WO2004009056A1 (fr) | 2002-07-23 | 2004-01-29 | Novartis Ag | Composition d'onguent ophtalmique comprenant un medicament, une base d'onguent et un agent de solubilisation/dispersion |
| US7288259B2 (en) | 2002-08-19 | 2007-10-30 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| US20040171561A1 (en) | 2002-09-03 | 2004-09-02 | Popp Karl F. | Topical formulations for treatment of rosacea |
| US7795203B2 (en) | 2002-09-30 | 2010-09-14 | Babizhayev Mark A | Method for topical treatment of eye disease and composition and device for said treatment |
| US20060188471A1 (en) | 2002-10-31 | 2006-08-24 | Podolsky Daniel K | Methods of treating epithelial lesions |
| GB0225795D0 (en) | 2002-11-05 | 2002-12-11 | Guillon Michael | Wipes |
| US20070269537A1 (en) | 2003-02-10 | 2007-11-22 | Bioderm Research | Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System |
| GB0322448D0 (en) | 2003-09-25 | 2003-10-29 | Lamellar Therapeutics Ltd | Using lamellar bodies to modify linear biological macro molecules |
| US20050197614A1 (en) | 2004-03-04 | 2005-09-08 | Wilson Pritchard | Occlusive biomedical devices, punctum plugs, and methods of use thereof |
| US8455016B2 (en) * | 2004-03-12 | 2013-06-04 | Melbj Holdings, Llc | Treatment for meibomian gland dysfunction or obstruction |
| US20050202097A1 (en) | 2004-03-12 | 2005-09-15 | Melbj Holdings, Llc, Florida | Lubricant for the ocular surface |
| EP1621191A1 (fr) | 2004-07-29 | 2006-02-01 | Werner Bollag | Traitement de maladies inflammatoires avec des antagonistes du RXR |
| US20090214676A1 (en) | 2005-04-30 | 2009-08-27 | Tissuetech, Inc. | Method for treating ocular demodex |
| WO2006137426A1 (fr) * | 2005-06-22 | 2006-12-28 | Kowa Company, Ltd. | Agent prophylactique ou thérapeutique pour une maladie cornéenne ou conjonctivale |
| US7981095B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
| US8915253B2 (en) | 2005-07-18 | 2014-12-23 | Tearscience, Inc. | Method and apparatus for treating gland dysfunction employing heated medium |
| WO2013003594A2 (fr) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Procédés et systèmes de traitement de dysfonctionnement de la glande de meibomius à l'aide d'énergie radiofréquence |
| US20070166402A1 (en) | 2005-12-12 | 2007-07-19 | Friedlaender Mitchell H | Compositions, methods and kits for removing debris from an ocular area |
| JP2009536525A (ja) | 2006-05-10 | 2009-10-15 | ディクステリティー ダイアグノーティクス | 化学反応性オリゴヌクレオチドプローブを使用した核酸標的の検出 |
| US8568790B2 (en) | 2006-05-31 | 2013-10-29 | Medihoney Pty Ltd. | Medicinal compositions containing honey |
| WO2008027069A1 (fr) | 2006-08-21 | 2008-03-06 | Tearscience, Inc. | Procédé et appareil de traitement du dysfonctionnement de la glande de meibomius au moyen d'un fluide |
| US8249695B2 (en) | 2006-09-29 | 2012-08-21 | Tearscience, Inc. | Meibomian gland imaging |
| US8090426B2 (en) | 2006-10-27 | 2012-01-03 | Felder Robin A | Microelectronic biosensor plug |
| US20100204317A1 (en) | 2006-11-03 | 2010-08-12 | Qlt Inc. | Methods of treating dermatological disorders or conditions |
| JP4987078B2 (ja) * | 2006-11-30 | 2012-07-25 | 株式会社メニコン | 眼科用組成物 |
| CN101668511A (zh) * | 2007-02-28 | 2010-03-10 | 阿西克斯医疗公司 | 正常化睑板腺分泌的方法和化合物 |
| US8128968B2 (en) | 2007-08-29 | 2012-03-06 | Tissuetech, Inc. | Compositions and methods for treating Demodex infestations |
| JP5668476B2 (ja) | 2007-10-08 | 2015-02-12 | オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物 |
| AU2009228205A1 (en) * | 2008-03-26 | 2009-10-01 | Eric Donnenfeld | Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics |
| WO2009134371A2 (fr) | 2008-04-30 | 2009-11-05 | Qlt Plug Delivery, Inc. | Insert lacrymal composite et procédés apparentés |
| EP2313157A2 (fr) | 2008-07-10 | 2011-04-27 | Allergan, Inc. | Dérivés de cyclosporine pour traiter des maladies et états oculaires et dermiques |
| US20120028929A1 (en) | 2008-09-19 | 2012-02-02 | Alacrity Bioscience, Inc. | Tetracycline stabilizing formulations |
| AU2010242866B2 (en) | 2009-05-01 | 2014-09-25 | Medtech Products Inc. | Cleanser compositions and methods for using the same |
| CN101612161A (zh) | 2009-08-07 | 2009-12-30 | 魏谠全 | 一种眼药组合物及其制剂 |
| PT2493474T (pt) * | 2009-10-30 | 2019-11-26 | Intratus Inc | Métodos e composições para libertação prolongada de fármacos |
| US20110294897A1 (en) | 2009-12-02 | 2011-12-01 | Bridge Pharma, Inc. | Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion |
| US20120093876A1 (en) | 2010-10-13 | 2012-04-19 | Aciex, Inc. | Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions |
| WO2012063237A2 (fr) | 2010-11-08 | 2012-05-18 | Healor Ltd. | Compositions ophtalmiques tamponnées et leurs procédés d'utilisation |
| US20130274214A1 (en) | 2010-12-29 | 2013-10-17 | Inspire Pharmaceuticals, Inc. | Method for treating blepharitis |
| JP5952302B2 (ja) | 2010-12-29 | 2016-07-13 | ニチャミン、ルイス・ディー | 眼の治療のための方法及びキット |
| WO2012092375A1 (fr) | 2010-12-29 | 2012-07-05 | Inspire Pharmaceuticals, Inc. | Méthode pour traiter l'œil sec |
| RU2599036C2 (ru) | 2011-01-26 | 2016-10-10 | Аллерган, Инк. | Андрогенная композиция для лечения офтальмологического заболевания |
| EA201391595A1 (ru) | 2011-05-20 | 2014-06-30 | Кейо Юниверсити | Новый металлопротеин, способ его получения и профилактический или терапевтический агент при заболеваниях роговицы или конъюнктивы, содержащий указанный металлопротеин |
| CA2840626A1 (fr) | 2011-06-29 | 2013-01-03 | Insite Vision Incorporated | Methodes permettant de traiter un dysfonctionnement recurrent des glandes de meibomius et de reduire la frequence de recurrence |
| ITFI20120044A1 (it) | 2012-03-01 | 2013-09-02 | Biodue Spa | Formulazione ad uso oftalmico comprendente olio di jojoba. |
| JP6470680B2 (ja) * | 2012-04-16 | 2019-02-13 | ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド | 皮膚および／または粘膜の処置および／またはケアのための組成物ならびに化粧品組成物または医薬組成物におけるその使用 |
| CA2888647A1 (fr) * | 2012-11-20 | 2014-05-30 | Revive Therapeutics Inc. | Utilisation de bucillamine dans le traitement de la goutte |
| US9211397B2 (en) * | 2012-12-19 | 2015-12-15 | Senju Usa, Inc. | Patch for treatment of eyelid disease containing clobetasol |
| US9987235B2 (en) * | 2013-08-01 | 2018-06-05 | Nicholas L. Abbott | Methods and compositions for modifying mucous membranes |
| CA2920815C (fr) | 2013-08-14 | 2021-09-21 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicreine plasmatique |
| MX2016013710A (es) * | 2014-05-07 | 2017-03-31 | Croma-Pharma Ges M B H | Solucion oftalmica acuosa y metodo para tratar el sindrome del ojo seco. |
| AU2015269353B2 (en) * | 2014-06-04 | 2020-03-26 | Tersus Pharmaceuticals, LLC | Methods of treating chronic dry eye disease using C16:1n7 palmitoleate and derivatives thereof |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| EP3313413A4 (fr) | 2015-09-28 | 2018-07-11 | Azura Opthalmics Ltd. | Agents contenant un thiol et un disulfure permettant d'augmenter la sécrétion lipidique des glandes de meibomius |
| BR112018070852B1 (pt) | 2016-04-14 | 2024-01-16 | Azura Ophthalmics Ltd | Composições de dissulfeto de selênio |
| EP3445352A4 (fr) * | 2016-04-19 | 2019-12-11 | Azura Opthalmics Ltd. | Compositions pour le traitement de troubles liés à l'hyperkératose |
-
2016
- 2016-09-28 EP EP16850455.3A patent/EP3313413A4/fr active Pending
- 2016-09-28 JP JP2018535266A patent/JP2018533622A/ja active Pending
- 2016-09-28 CA CA3000088A patent/CA3000088A1/fr not_active Abandoned
- 2016-09-28 CN CN202110338196.5A patent/CN113144203A/zh active Pending
- 2016-09-28 KR KR1020187011382A patent/KR20180090251A/ko unknown
- 2016-09-28 WO PCT/IB2016/001510 patent/WO2017055924A2/fr active Application Filing
- 2016-09-28 US US15/279,301 patent/US10688122B2/en active Active
- 2016-09-28 AU AU2016332966A patent/AU2016332966A1/en not_active Abandoned
- 2016-09-28 CN CN201680069405.8A patent/CN108472312A/zh active Pending
-
2020
- 2020-02-19 US US16/795,497 patent/US20200179440A1/en not_active Abandoned
- 2020-12-11 JP JP2020206141A patent/JP7138694B2/ja active Active
-
2021
- 2021-11-29 US US17/536,986 patent/US20220226367A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533622A5 (fr) | ||
| US20220226367A1 (en) | Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2019513775A5 (fr) | ||
| JP2013035860A5 (fr) | ||
| BR112022011951A2 (pt) | Tratamento de esclerose lateral amiotrófica e distúrbios relacionados | |
| NZ591025A (en) | Formulation for oral administration of proteins | |
| RU2013111954A (ru) | Способ лечения от бокового амиотрофического склероза | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| JP2013501805A5 (fr) | ||
| AR068901A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
| ES2288641T3 (es) | Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta. | |
| BR112021025531A2 (pt) | Moduladores de pirazol-piridona farmacêuticamente ativos da nedilação de cullin mediada por dcn1/2 | |
| RU2015115398A (ru) | N-ацетил-L-цистеин для применения в экстракорпоральном оплодотворении | |
| ES2242780T3 (es) | Medios para la terapia adyuvante de la demencia que comprenden el acido alfa-lipoico. | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| WO2020227578A1 (fr) | Formulations d'acide lipoïque | |
| CA3223719A1 (fr) | Compositions et methodes d'amelioration de la vision | |
| JP2018177773A (ja) | 医薬 | |
| Nyfos | A comparative clinical study of a new antirheumatic agent, tolfenamic acid (Clotam), and Phenylbutazone in rheumatoid arthritis |